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 There are currently still no approved antiviral drugs to treat or prevent chikungunya 
virus (CHIKV) infections despite the fact that this arbovirus continues to cause outbreaks in 
Africa, Asia, and South- and Central-America. Thus 20 new conjugated compounds in the 
families of bis(benzofuran–1,3-thiazolidin-4-one)s and bis(benzofuran–1,3-thiazinan-4-one)s 
were designed based on the structural features of suramin. These new compounds were 
synthesized by chemical methods and their structures were confirmed spectroscopically. In 
CPE reduction assays, six of these new bis-conjugates inhibited CHIKV replication in Vero 
E6 cells with EC50 in the range of 1.9 to 2.7 µM and selectivity index values of ~75 or higher. 
These results and compounds provide a starting point for further optimization, design, and 
synthesis of new antiviral agents for this (re)emerging disease.  
1. Introduction  
 Chikungunya virus (CHIKV) is an arthrogenic alphavirus, which has infected millions 
of people since its re-emergence in 2005, when it caused large outbreaks in Asia and Africa. 
In 2013, CHIKV emerged in the Caribbean (Weaver, 2014; Weaver and Lecuit, 2015) and 
started another massive outbreak, which has thus far resulted in >1.2 million cases in the 
Americas alone. At the moment there are no approved vaccines or specific antiviral drugs to 
prevent or treat chikungunya disease (Hwu et al., 2017). Several molecules with inhibitory 
effects on CHIKV in cell culture, and in some cases in animal/mouse models, have been 
reported (Kuo et al. 2016), but none of them has advanced into clinical trials (Abdelnabi et al. 
2017).  
 Our laboratories have previously developed several new compounds with activity 
against CHIKV (Hwu et al., 2015; Albulescu et al., 2015). The first class of these 
compounds consists of uracil–coumarin–arene conjugates and the second class concerns 
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suramin (1) and its derivatives. Suramin inhibits CHIKV replication through multiple 
mechanisms (Kuo et al. 2016; Albulescu et al., 2015), mainly by interfering with an early 
step of the replication cycle, but with (minor) additional effects on later steps, like RNA 
synthesis. Recently, suramin has also been reported to inhibit Zika virus replication by 
interfering with virus attachment and release of infectious particles (Albulescu et al. 2017). 
Suramin is a symmetric molecule with a urea (NH–CO–NH) group in the center as 
the “neck”, two benzamido moieties as the “shoulder”, two methylbenzamido moieties as the 
“arms”, two naphthalene rings as the “palms”, and six sulfonate groups as the “fingers”.  A 
tetra-sulfonate derivative of suramin that lacks two sulfonate groups is less active against 
CHIKV compared with suramin (Albulescu et al., 2015), although it inhibits human and 
murine norovirus RNA-dependent RNA polymerase (RdRp) activity in vitro with an IC50 of 
28 nM (Croci et al., 2014). Of a series of eleven suramin-related analogs that were tested for 
their ability to inhibit CHIKV RNA synthesis in vitro and to inhibit CHIKV replication in 
cell culture, only three exhibited inhibitory activity. All of these had features very similar to 
suramin (Albulescu et al., 2015).  
 Several other synthetic compounds with a dimeric structure similar to suramin also 
show significant biological activities. Prominent examples include atracurium besilate 
(Hughes, 1986), cisatracurium besilate (Bryson and Faulds, 1997), cromoglicic acid 
(Penumutchu et al., 2014), daclatasvir (Press release, 2015), ombitasvir (Press release, 2014), 
and pentamidine (Nguewa et al., 2005). Among them, daclatasvir (trade name Daklinza) and 
ombitasvir (trade names Viekira Pak and Technivie) are antiviral drugs for the treatment of 
hepatitis C virus infection. The structural “widths” of these two dimeric antiviral compounds 
are around 22.4 and 24.5 Å, respectively.  
 Benzofuran is one of the most important oxygen-containing heterocycles (Khanam 
and Shamsuzzaman, 2015). Many benzofuran derivatives display potent biological and 
pharmacological properties, such as β-adrenoceptor antagonistic (Narimatsu et al., 2003), 
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analgesic, anti-arrhythmic (Spaniol et al., 2001), anti-Alzheimer’s, anti-dermal, anti-
feedantic, anti-hyperglycemic, anti-inflammatory, anti-microbial, anti-pyretic, anti-tumor, 
immunosuppressive (Cheng et al., 2010; González–Gómez et al., 2005; Khanam and 
Shamsuzzaman, 2015; Kao and Chern, 2001), and especially antiviral activities (Naik et al., 
2015; He et al., 2015). Moreover, the broad and potent activities of 1,3-thiazolidin-4-ones 
have established these compounds as biologically important scaffolds. Their biological 
properties include anthelmintic, anti-bacterial, anti-cancer, anti-convulsant, anti-diabetic, 
anti-fungal, anti-histaminic, anti-hyperlipidemic, anti-inflammatory, anti-proliferative, anti-
tubercular, cardiovascular, follicle stimulating hormone receptor agonist, hypnotic (Verma 
and Saraf, 2008; Tripathi et al., 2014; Gouvea et al., 2016), and anti-viral activities as well 
(Barreca et al., 2002; Rao et al., 2004; Rawal et al., 2007). Recently, thiazinanone derivatives 
have been reported with medicinally important roles. These compounds show potent HIV-RT 
inhibitory, cyclooxygenase (COX-2) inhibitory (Zebardast et al., 2009), anti-dyslipidemic, 
anti-hyperglycemic, anti-tumor (Kamel et al., 2010), anti-malarial (Rudrapal et al., 2013), 
and anti-fungal activities (Verma et al., 2010; Qu et al., 2013). Accordingly, using suramin 
(1) as a model, we designed bis(benzofuran–1,3-thiazolidin-4-one) derivatives 2 and 
bis(benzofuran–1,3-thiazinan-4-one) derivatives 3 as new types of dimeric compounds, of 
which the antiviral activities were tested. Suramin (1) and bis-benzofurans 2 and 3 have a 
width of ~23.6 Å (between the two naphthalene rings), 22.7 Å, and 21.7 Å (between the two 
benzene rings), respectively, on the basis of the conformations shown in structures 1–3. Raj 
and co-workers (Raj et al., 1998) reported that the two naphthalene rings either fold closer 
to each other with a distance of ~16–20 Å or stretch away from each other at a ~28–30 Å 
distance. We aimed to use the two new types of dimeric 
conjugates to develop leads against CHIKV. In total, 20 new conjugated compounds and one 






























efficacy against CHIKV. The structure–activity relationships of these bis(benzofuran–
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2.  Materials and methods  




3.  Results and discussion 
3.1 Synthesis of New Conjugated Dimers and Their Structural Identification (Scheme 
1)  
 The target compounds with the scaffolds of 2 and 3 were obtained from the 
common intermediate bisbenzofuran-2-al 7. Its preparation started with coupling 
bissalicyaldehyde 4 (Delogu et al., 2010) with commercially available bromoacetaldehyde 
diethyl ether (5) in the presence of K2CO3 (s) in dry DMF (Scheme 1). After the reaction 
mixture was heated to 120 °C, it gave the desired diacetal 6. Using acetic acid as the 
catalyst and also as the solvent, this diacetal 6 underwent sequential deacetylation, 
intramolecular aldol condensation, and acid-catalyzed dehydration at 110 °C. The desired 
benzofuran-2-al dimer 7 was generated in 88% yield and purified as yellow crystals with 
mp 150.2–151.6 °C. Then alkyl-, cycloalkyl-, aryl-, and aralkylamines 8a−j were used to 
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condense with bisbenzofuranal 7 in excess in dry methanol to give bisimines 9a−j as solids 
in 83−94% yields.  
 Subsequent ring formation through condensation of bisimines 9a−j with 2-
mercaptoacetic acid (10) in benzene at 90 °C led to the desired targets 2a−j as solids in 77–
88% yields. The structures of all these new bis(benzofuran–1,3-thiazolidin-4-one)s were 
identified on the basis of their spectroscopic characteristics. For example, the exact mass of 
compound 2g was measured as 534.1651 for M+, which is very close to its theoretical value 
of 534.1647 for the species (C29H30N2O4S2)+. The generation of two thiazolidinone rings is 
supported by presence of two NCHS protons as a doublet with a long-range coupling with 
 
Scheme 1. Synthetic procedures for generating the targets bis(benzofuran–thiazolidin-
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only one of the two SCH2C=O protons to give a J4 = 1.2 Hz at 5.72 ppm in the 1H NMR 
spectrum (Cunico et al. 2006). The two sets of diastereotopic SCH2C=O protons in the 
thiazolidinone ring resonated at 4.00 ppm as a double of doublet with a J2 = 15.2 and J4 = 
1.2 Hz and at 3.53 ppm as a doublet with J2 = 15.2 Hz. The center of this compound 
contained a methylene joint, in which the CH2 resonated at 4.10 ppm. It also exhibited a 
multiplet at 4.33−4.26 ppm for two protons due to the two CHMe2 groups attached to two 
separated nitrogen atoms in thiazolidinone rings. The twelve methyl protons of two 
isopropyl groups showed resonance as a doublet with a J = 6.8 Hz at 1.27 and 0.87 ppm. 
The NC=O carbon resonated at 171.1 ppm in the 13C NMR spectrum and the amido C=O 
group exhibited a strong absorption band at 1673 cm–1 in the IR spectrum. These 
observations are consistent with those reported by Srivastava and co-worker (Srivastava 
et al., 2007).  
Attempts to synthesize bis(benzofuran–1,3-thiazinan-4-one)s 3 from bisimines 9a−j 
and 3-mercaptopropionic acid (11) using the same cyclization conditions described above 
(for 2a-j) resulted in low yields (<15%). After many trials, the use of N,N'-
dicyclohexylcarbodiimide (DCC, 2.5 equiv) as an activating agent (Valeur and Bradley, 
2009) in THF led to the conjugated compounds 3a−j as solids in 76–84% yields. For 
bis(benzofuran–thiazinanone) 3g, the two NCHS protons of thiazinanone rings showed a 
singlet at 5.59 ppm in the 1H NMR spectrum. The four SCH2C=O protons in the 
thiazinanone ring resonated as multiplet at 3.07–2.98 and 2.79–2.73 ppm. The NC=O 
carbon resonated at 169.0 ppm in the 13C NMR spectrum and the amido C=O group in the 
six-membered rings exhibited a strong absorption band at 1655 cm–1 in the IR spectrum.  
3.2 Evaluation of Anti-CHIKV Activity 
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 The antiviral activity of bis(benzofuran–1,3-thiazolidin-4-one)s 2 and 
bis(benzofuran–1,3-thiazinan-4-one)s 3 was first analyzed in cytopathic effect (CPE) 
reduction assays with CHIKV by testing four different concentrations (i.e., 100, 25, 6.3, 
and 1.6 µM) in two independent experiments. Only compounds that showed at least 50% 
protection against CHIKV-induced CPE in this primary screen were selected for 
validation in a secondary screen. In that case, eight 2-fold serial dilutions of compounds 
with an initial starting concentration of 200 µM were analyzed (in quadruplicate) to 
determine the EC50. Cytotoxicity was analyzed in parallel in uninfected cells to determine 
the CC50. The obtained values were used to determine the selectivity index (SI = 
CC50/EC50), a measure for the therapeutic window of the compound in the assay system.  
Among the 20 new conjugated compounds and one bisaldehyde intermediate 7 
shown in Scheme 1, three 1,3-thiazolidin-4-ones (i.e., 2f, 2g, and 2j) and three 1,3-
thiazinan-4-ones (i.e., 3f, 3g, and 3i) exhibited limited inhibition of CHIKV replication in 
Vero E6 cells. Their EC50 values ranged from ~1.5 to 2.7 µM (see Table 1) and their 




Table 1. Inhibition of CHIKV by bis-benzofuran conjugates. EC50 values were determined by 
CPE reduction assays on Vero E6 cells infected with CHIKV LS3. CC50 values were 
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aCytotoxicity of the compounds in uninfected cells, the concentration of compound that 
reduced cell viability (measured by MTS assay) to 50% of that of untreated cells. bEC50, 






























































cell death (CPE) as determined in CPE reduction assays. cSelectivity index. The table lists 
the average values of two independent experiments, performed in quadruplicate. 
*Estimate, compounds were toxic and cell viability was only 60-70% viability at 
concentrations above 3-6 µM. Therefore, full protection (100% viability) was never 
observed and the concentration that gave half of the maximum effect (~30-35% viability) 
is reported. Log P values were determined as described in the text and are an average of 
three independent experiments. 
Although the CC50 values of compounds 2f, 2g, 3f, 3g, and 3i were >200 μM, many 
other conjugated compounds had clear negative effects on cell viability. Approximately 
20-30% reductions in cell viability were observed for several of these compounds starting 
already at low concentrations. As a result of this toxicity, we did not observe full 
protection (100% viability) in the CHIKV CPE reduction assays and therefore we could 
not accurately determine the true EC50 value of most of these compounds, but only 
determine the concentration that gave half of the maximum protective effect (which is 
indicated with ~ and * in Table 1). We cannot exclude that (part of) the antiviral effect of 
compounds that adversely affected the host cell metabolism is the result of pleiotropic or 
non-specific effects on the host cell. However, it should be noted that a high 
concentration (200 μM) of the most promising compound 2g, did not lead to serious 
cytotoxicity, as viability remained 77%.  
All of the 20 new compounds 2 and 3 were also screened for antiviral activity 
against the related Sindbis virus (SINV) and Semliki Forest virus (SFV) in CPE reduction 
assays. None of the compounds inhibited SINV. While compound 2h had some inhibitory 
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effect on Semliki Forest virus, this was likely related to cytotoxicity. Only bis(benzofuran–
thiazinanone) 3h protected cells from SFV-induced CPE with an EC50 of 34.8 μM and an 
SI of >5.74. The fact that none of the compounds that showed some protective effect 
against CHIKV was active against SINV or SFV suggests that the anti-CHIKV effect is not 
(only) merely due to nonspecific negative effects on the host cell. Suramin has been 
reported to interfere with binding of a variety of viruses to their host cells ((Albulescu et 
al. 2017 and references therein). Therefore, the bis-conjugated compounds that inhibit 
CHIKV replication in the CPE-based assay might do so by interfering with attachment of 
the virus to Vero E6 cells, although it cannot be excluded that these molecules (also) 
inhibit later steps of the replication cycle. Studies to elucidate the exact mode of action of 
these compounds are currently ongoing. 
3.3 Lipophilicity and Potential “Drug-like” Bis-conjugates 
The ‘‘shake–flask method’’ (Kraszni et al., 2003) was applied to obtain the 
molecular lipophilicity (quantified as log P) values of bis-conjugated compounds with 
promising activities in the antiviral assays (Table 1). Thus n-octanol and pH 7.4 phosphate 
buffer were mutually saturated and the phases were separated. Stock solutions of thebis-
conjugated compound were prepared in pH 7.4 phosphate buffer and these  were partitioned 
between n-octanol and pH 7.4 phosphate buffer. The phase mixtures were shaken for 60 min 
at constant 25 °C. After separation, the absorbance of the phosphate buffer solutions was 
measured by UV spectrophotometry. The P value corresponds to the quotient of the 
concentrations of the bis-conjugated derivatives between n-octanol and phosphate buffer.  
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Molecular lipophilicity of chemical entities often plays an important role in the 
development of drug leads (Hann et al., 2012) and log P values between −0.4 and 5.6 are 
regarded to be in a good range for “drug-like” molecules (Ghose et al., 1999).  
Among the new compounds with promising EC50 and SI values, the log P values of 
bis-conjugates 2f, 2g, 2j, 3f, 3g, and 3i fell into the range of 4.07–5.52. Therefore, these 
seven compounds have some potential as “drug-like” candidates for future development. 
3.4 Structure−Activity Relationship:  Essential Moieties and Substituents  
The bis-conjugated compounds with either two five-membered 1,3-thiazolidin-4-
one rings or two six-membered 1,3-thiazinan-4-one rings as the “arms” showed comparable 
EC50 for CHIKV and had similar log P values ( compounds 2f,g,j and 3f,g,i in Table 1). The 
substituents attached to the nitrogen atoms played a determining role in the anti-CHIKV 
activity, as all six active compounds had alkyl substituents as the “palms” such as ethyl, 
isopropyl, cyclopropyl, and methoxyethyl groups. When the palms were phenyl or 
benzyl groups with various substituents as the “fingers” in bis-conjugates 2a−e and 3a−e 
the antiviral activity was lost.  
Suramin 1 has anti-CHIKV activity and some of its structural bis-analogs that were 
designed on the basis of its skeleton also exhibited significant inhibitory activity towards 
CHIKV (see Table 1). Thus the “urea neck” in suramin can be replaced by a simple 
“methylene neck” in bis-benzofuran conjugates. Replacement of the benzamido moieties 
of suramin with benzofuran nuclei in bis-conjugates 2 and 3 as the “shoulders” allowed us 
to successfully obtain compounds 2f,g,j and 3f,g,i as anti-CHIKV drug leads. Based on the 
anti-viral activities of the tested compounds, the six-membered thiazinanone ring could be 
considered superior to the five-membered thiazolidinone ring. Moreover, the six dimeric 
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compounds in the family of bis(benzofuran–1,3-thiazolidin-4-one)s and bis(benzofuran–1,3-
thiazinan-4-one)s exhibited a ~29 -42 times more potent anti-CHIKV activity than suramin 
although their toxicity remains an issue to be solved. 
 
4. Conclusions  
With the aim to develop small molecules with anti-CHIKV activity, 20 new 
benzofuran–1,3-thiazolidin-4-one and benzofuran–1,3-thiazinan-4-one conjugated 
compounds in dimeric form were designed and synthesized. Six of them (i.e., 2f,g,j and 
3f,g,i) inhibited CHIKV replication with EC50 values in the range of 1.9–2.7 µM. These 
compounds had up to 42 times lower EC50 values than suramin. However, full protection 
against CHIKV-induced CPE was not observed due to (limited) cytotoxicity of the 
compounds at higher concentrations. Further medicinal chemistry efforts are required to 
reduce the toxicity of the compounds, while retaining or improving their antiviral effect. 
Nonetheless, these results indicate that the synthesis of the basic skeletons of dimeric 
benzofuran–1,3-N,S-heterocycle conjugates provides a new avenue in the development of 
antiviral leads. The 1,3-N,S-heterocyclic nuclei could be either a five- or a six-membered 
ring. The mechanism of action of these new CHIKV inhibitors is currently under 
investigation.  
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